New York/R&D/CTR/Translational Med/Ther
Publicly observedNew Rochelle, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | New Rochelle | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | New York/R&D/CTR/Translational Med/Ther | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | JBDNWL5M9D43 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jul 2024Publicly observed
NIH SBIR/STTR award: Exosome drug for tendinopathy
USD 719,580.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2024Publicly observed
NIH SBIR/STTR award: Exosome drug for tendinopathy
USD 719,580.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.